1. In Vivo

Deals Shaping The Medical Industry, December 2017

 
• By Beth Allan, Deanna Kamienski, and Maureen Riordan

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.

Dealmaking

Leica Biosystems Ltd. and Clearbridge BioMedics Pte. Ltd. will co-promote each other’s automated systems for liquid biopsy and circulating tumor cell (CTC) analysis. (Nov.)

Included in the deal are ClearBridge’s ClearCell FX, an automated cell retrieval system that allows for the collection of intact and viable CTCs from small amounts of blood obtained in a standard blood draw. The platform, which is powered by the company’s CTChip FR1 microfluidics biochip, provides a CTC sample with high cell surface antigen expression and cell integrity, and once output, is immediately ready for downstream analysis through pathology workstations such as Leica’s BOND RX

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.